The Validation of a Novel Adherence Method for Oral Oncolytics

Completed · Not applicable

Conditions studied: Cancer

In brief

The long-term goal of this research is to apply technologic approaches to improve the use of oral oncolytics. The objective of this study is to assess patient adherence to oral oncolytics and to validate a currently available smart phone application (iRxReminder) partnered with an automated dispensing device, a "Pod", in affecting patient adherence. The rationale for this study is that medication adherence to oncolytics varies and strategies are needed to improve it.

Key facts

Study ID

NCT03561272

Run by

University of Michigan Rogel Cancer Center

People needed

18

Starts

2017-06-20

Expected to finish

2018-10-31

Last updated by the study team

2019-10-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must be > 18 years of age
• Must have a smart phone
• Must be able to have their oral oncolytic filled at the University of Michigan Comprehensive Cancer Center pharmacy and be newly prescribed Capecitabine (Xeloda).

You may not qualify if…

• Patients who do not have a smart phone
• Patients who have a serious mental illness or cognitive impairment, e.g., psychosis or dementia.
• Patients who do not speak English
• Patients who cannot fill their oral oncolytic prescription at the University of Michigan Comprehensive Cancer Center Pharmacy

Where it is running

• The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.